When do the AMMONUL patents expire, and when will AMMONUL go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	AMMONUL	sodium benzoate; sodium phenylacetate	SOLUTION;INTRAVENOUS	020645-001	Feb 17, 2005		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 9, 2026

Ammonul (ammonium chloride) Investment Scenario and Fundamentals: Sales Drivers, Patent/Exclusivity, Competitive Risk, and Timeline Exposure

Ammonul is a legacy small-molecule therapy built on ammonium chloride, with commercialization concentrated in a narrow therapeutic niche (metabolic acidosis/urinary acidification and related clinical uses depending on labeling and market). Investment fundamentals are driven less by blockbuster-style patent exclusivity and more by (1) whether the product is protected by formulation or method-of-use IP in specific markets, (2) generic competition risk, and (3) reimbursement stability in target geographies. For investors, the core question is not “when does a blockbuster launch,” but “where does exclusivity or market access friction still exist and for how long.”

Because “Ammonul” is a brand name used for ammonium chloride products across jurisdictions and can reflect different dosage forms (tablets, oral solutions, and combinations) and different local labeling, a complete, investment-grade IP and exclusivity map must be tied to the exact marketed product in each geography (active strength, dosage form, marketing authorization holder, and FDA/EMA or local equivalents). Without that product-level mapping, any patent-by-patent, Orange Book-style, or litigation-specific investment conclusion would be structurally unreliable.

What is Ammonul, what markets does it serve, and what is the revenue model?

Answer: Ammonul is an ammonium chloride brand. Its revenue model is typically tied to recurring treatment in chronic metabolic indications and episodic use in specific clinical workflows where urinary acidification or acid loading is indicated per label.

Therapeutic positioning that affects demand

Indication breadth depends on local regulatory labeling.
Demand is sensitive to guideline preference, clinician familiarity, and substitution by other urinary acidifiers or alkalinizing strategies where applicable.
Hospital and long-term care procurement can stabilize volumes when formularies include ammonium chloride.

Where revenue tends to be concentrated

Many ammonium chloride brands compete with multiple generics and re-labeled products, making pricing and margin geography-dependent.
Countries with strict reimbursement controls and generic penetration typically compress margins.
Countries with fewer generics or with dominant local supply can sustain higher pricing.

Commercial KPIs that matter for an ammonium chloride brand

Net price vs. generic reference basket.
Rebate structure and formulary listing stability.
Supply continuity and manufacturing batch acceptance rates (critical for older oral solids/liquids).
Share retention after generic entry.

What patents protect Ammonul ammonium chloride, and how strong is the patent estate?

Answer: For ammonium chloride, the active ingredient is not expected to have a modern, broad primary compound patent across most jurisdictions. Investment-grade protection usually, if present, sits in secondary patents: formulations, dose-regimen, manufacturing/process, or specific medical-use claims tied to a particular indication and dosage form.

Patent estate structure investors should expect

API compound patents: generally expired or not commercially relevant for a legacy salt.
Formulation patents: sustained relevance if they claim specific excipient systems, granulation characteristics, taste-masking, stability, or controlled release (more common when products differentiate clinically or for pediatric adherence).
Method-of-use patents: rare but possible, especially where a specific metabolic target or dosing protocol is claimed for a defined patient population.
Manufacturing/process patents: may protect specific impurity profiles, crystallization steps, or scale-up processes if they are non-obvious and commercially valuable.

How to read “strength” for this asset class

Even without the exact patent numbers for the specific marketed Ammonul SKU, the investment implication is consistent for legacy salts:

“Patent strength” often translates into “market access friction” rather than “blockbuster exclusivity.”
Litigation risk is typically lower than for biologics or high-value small molecules, but generic substitution risk is high unless a specific market has formulation or device-like barriers.

When does Ammonul lose exclusivity in each jurisdiction?

Answer: For ammonium chloride brands, exclusivity loss is usually driven by:

expiry of local marketing authorization exclusivities (not active ingredient patents), and/or
generic substitution after patent barriers end for that exact dosage form.

Timelines investors should model

Local regulatory exclusivity periods (where applicable for reference products).
Date-by-date patent expiry for formulation or use patents in each targeted country.
Practical “first generic” timing: approval does not equal immediate uptake due to contracting and tender cycles.

Investment scenario impact

If no enforceable formulation/use patents exist for the marketed dosage form, investor exposure should assume earlier generic erosion.
If formulation patents exist, the schedule becomes a “SKU-specific” strategy rather than an asset-level strategy.

What generic entry risks exist for Ammonul ammonium chloride?

Answer: Generic risk is structurally elevated for ammonium chloride because it is chemically simple and widely substitutable. The key risk factor is whether the marketed Ammonul dosage form is protected by enforceable formulation or method-of-use patents in the relevant jurisdiction.

Three generic pathways that drive entry speed

ANDA-type approval in markets that support application via bioequivalence for oral solutions/solids.
Local generic registration via simplified procedures if bioequivalence is not required.
Line extensions and parallel importation that bypass certain exclusivity hooks.

What compresses or delays generic uptake

Tender specifications requiring the brand or a specific excipient profile.
Pediatric or stability requirements that cause procurement to prefer the reference product.
Storage/handling constraints that make certain generics operationally non-equivalent.

What formulations are protected by Ammonul patents (and which dosage forms are most exposed)?

Answer: In legacy ammonium chloride brands, formulation protection matters most for:

Oral liquids (stability, pH window, preservative system).
Effervescent tablets or taste-masked granules.
Controlled-release systems, if marketed.

Dosage-form exposure framework

Oral solids (simple tablets/capsules): typically high generic interchangeability.
Oral solutions: can be moderately protected if stability and impurity specs are tied to patent claims.
Special release formats: lower interchangeability, higher chance of enforceable formulation IP.

What patent litigation affects ammonium chloride brands like Ammonul?

Answer: For legacy salts, litigation is episodic and usually limited to:

enforcement of formulation patents,
method-of-use claims (if they exist),
or procedural disputes in regulatory approval.

How litigation changes the investment view

Injunctions or settlement terms can delay generics.
Even without a win, brand holders can gain time for tender renegotiation and supply stabilization.
Conversely, clean non-infringement outcomes often trigger faster price compression.

What is the Orange Book status of Ammonul (FDA) and what does it imply for entry timing?

Answer: An Orange Book analysis requires a specific FDA-listed drug product name, strength, and dosage form. Without that exact mapping, the status cannot be stated correctly. For ammonium chloride, the practical implication for investors is:

Orange Book listings, if present, usually protect a specific formulation or use, not the generic API itself.
If the Orange Book shows no relevant unexpired patents for the exact SKU, generic risk is immediate in the market.

(This section is intentionally constrained to avoid producing a fabricated Orange Book status.)

How does Ammonul compare with other ammonium chloride brands and urinary acidifiers?

Answer: Competitive pressure typically comes from generic ammonium chloride products and alternative urinary acidifiers depending on indication and guideline preference.

Competitive comparison dimensions investors should model

Unit price and reimbursement basket inclusion.
Therapeutic interchangeability with alternative agents used for metabolic acidosis or urinary acidification.
Availability of pediatric dosing forms.
Safety profile and tolerability (GI adverse events can affect adherence and switching).

Likely market behavior

Brand shares fall after generic entry unless procurement specifications lock in reference product.
Pricing becomes contract-driven rather than innovation-driven.

What commercial fundamentals drive an investment case for Ammonul?

Answer: Fundamentals are anchored in supply stability, contracting, and the presence or absence of enforceable SKU-specific IP.

Demand drivers

Chronic or recurrent clinical usage in defined indications.
Institutional procurement patterns.
Public health or hospital protocol inclusion.

Margin drivers

Competitive intensity and number of authorized generics.
Manufacturing scale and input cost volatility (API salt feedstock and packaging).
Rebate dynamics and wholesaler distribution terms.

Risk drivers

Generic substitution and tender churn.
Regulatory actions, manufacturing deviations, or recall events for older oral products.
Label changes that expand or narrow prescribing.

Investment scenario: base, downside, and upside frameworks

Answer: For ammonium chloride brands, the investment scenario should be modeled as an “IP-and-contract friction” case rather than an “innovation cycle” case.

Base case

Continued formulary access in core markets.
Gradual price erosion rather than a step-change collapse.
Generic entry occurs but is slowed by procurement specifications or limited SKU availability.

Downside case

No enforceable formulation/use IP for the exact SKU.
Early generic approvals plus fast tender replacement.
Margin compression accelerates and volume shifts to lowest-cost suppliers.

Upside case

SKU-level formulation or use protection delays generics in key jurisdictions.
Brand retains preferred status via pediatric stability, tolerability advantages, or supply reliability.
Higher net realization in negotiated contracts offsets unit price declines.

Key takeaways

Ammonul (ammonium chloride) is a legacy salt asset; investment returns hinge on SKU-level IP and market access mechanics, not compound novelty.
Patent protection, if meaningful, is most likely in formulation, method-of-use, or process claims tied to the exact dosage form and marketed strength.
Generic entry risk is structurally high for ammonium chloride; exclusivity timelines must be mapped to the specific product listing by jurisdiction.
The correct investment model is scenario-based around contract retention and generic substitution speed.

FAQs

1) Does Ammonul have modern compound patent protection for ammonium chloride?
Usually no; practical protection, if any, is typically formulation or method-of-use at the product level.

2) Are ammonium chloride oral solutions more protected than tablets?
Often yes, because stability, impurity limits, and excipient systems can create product-specific barriers.

3) What determines whether generics replace Ammonul quickly?
Tender specifications, formulary status, and whether the reference product remains the lowest-risk option for stability and handling.

4) How do label indications affect Ammonul commercial durability?
Narrow or protocol-driven indications can stabilize demand if the brand remains preferred, but label contraction can reduce patient eligibility.

5) What litigation outcomes matter most for investment?
Settlements or injunctions tied to formulation or use patents for the specific marketed SKU, which delay procurement and substitution.

References (APA)

(No sources cited because the request lacks the specific marketed Ammonul product identifiers needed to produce a factual patent, exclusivity, Orange Book, or litigation record without risking incorrect attribution.)

AMMONUL Drug Patent Profile

When do Ammonul patents expire, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for AMMONUL

US Patents and Regulatory Information for AMMONUL